On Tuesday, Shares of Micron Technology, Inc. (NASDAQ:MU), closed flat at $24.24, despite Technology stocks were higher Tuesday with shares of technology companies in the S&P 500 rising about 0.6% in afternoon trade.
On June 2, Micron Technology, Inc. declared a new addition to its expansive portfolio of flash storage products, providing a purpose-built solution for cost-sensitive consumer applications seeking high performance and reliability. The new TLC NAND is built on their 16-nanometer (nm) process and delivers a balanced set of features for applications like USB drives and consumer solid state drives. The market appetite for TLC is projected to be strong throughout 2015, constituting almost half of the total NAND gigabytes shipped.
Micron’s 16nm process—recognized by TechInsights as the Most Innovative Memory Device and 2014 Semiconductor of the Year—is a mature and proven storage technology, making it an excellent foundation for a reliable TLC design. TLC, or triple-level cell, is a technology that fits three bits in every flash data cell, creating greater cost and size efficiency.
Customers of the technology will benefit from Micron’s extensive design support team, who act as trusted advisors to ensure smooth qualification and optimal end-solution performance. Key flash customers and ecosystem partners worldwide have already begun working to integrate this new NAND with their latest designs, ensuring quick adoption in end applications.
Micron Technology, Inc., together with its auxiliaries, provides semiconductor solutions worldwide. The company manufactures and markets dynamic random access memory (DRAM), NAND flash, and NOR flash memory products; and packaging solutions and semiconductor systems.
Shares of Delta Air Lines, Inc. (NYSE:DAL), declined -0.32% to $40.57, during its last trading session.
Delta Air Lines, will enter into an aircraft acquisition deal with The Boeing Co. for 20 Embraer E190 aircraft and 40 additional new 737-900ERs upon ratification of a tentative agreement covering more than 12,000 Delta pilots. The tentative agreement was approved for membership ratification recently by the Delta Master Executive Council (MEC) of the Air Line Pilots Association (ALPA).
The tentative agreement provides enhancements to overall pilot compensation—counting base pay enhances—together with a revision of the airline’s profit sharing formula startning in 2016. Additionally, this accord would secure additional career advancement opportunities for Delta pilots while providing the airline with productivity enhancements and further fleet flexibility across the airline’s U.S. domestic system.
The MEC will put the tentative agreement out to pilots for a ratification vote. If approved, the agreement would have an amendable date of Dec. 31, 2018.
Delta Air Lines, Inc. provides planned air transportation for passengers and cargo worldwide. The company operates in two segments, Airline and Refinery. Its route network comprises various gateway airports in Amsterdam, Detroit, Los Angeles, Minneapolis-St. Paul, New York-LaGuardia, New York-JFK, Paris-Charles de Gaulle, Salt Lake City, Seattle, and Tokyo-Narita.
Finally, Alkermes plc (NASDAQ:ALKS), ended its last trade with 10.12% gain, and closed at $64.52.
Alkermes Public Limited Company, declared that data from studies of the company’s pipeline of central nervous system (CNS) drug candidates in schizophrenia and depression, counting ALKS 3831, aripiprazole lauroxil and ALKS 5461, will be presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Miami, Fla., June 22-25, 2015.
Alkermes data presentations at ASCP comprise:
ALKS 3831
- Oral presentation, “ALKS 3831: A Novel Drug Candidate for the Treatment of Schizophrenia,” will be presented during the Pharmaceutical Pipeline symposium on Monday, June 22, 2015, 2:00 p.m. – 4:00 p.m. EDT.
- Poster #T6, “ALKS 3831: A Novel Drug Candidate for the Treatment of Schizophrenia,” will be accessible during Poster Session I, Tuesday, June 23, 2015, 11:15 a.m. – 1:00 p.m. EDT.
- Oral presentation, “A Phase 2, Randomized, Olanzapine-Controlled Study of the Safety, Tolerability and Efficacy of ALKS 3831 in Adults with Schizophrenia,” will be presented on Tuesday, June 23, 2015, 3:30 p.m. – 4:30 p.m. EDT.
Alkermes Public Limited Company, an integrated biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in various therapeutic areas.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
